Engineered immune cells take on Hard-to-Treat prostate cancer
NCT ID NCT06046040
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new treatment called TmPSMA-02 for men with metastatic castrate-resistant prostate cancer that has progressed after standard therapies. The treatment uses the patient's own immune cells (T cells) that are genetically modified to recognize and attack prostate cancer cells while also resisting the tumor's attempts to shut them down. Up to 30 participants will receive the cells in increasing doses to find the safest dose and to see if the therapy can shrink tumors or slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TmPSMA-02 CAR T cells (a patient's own immune cells modified to target prostate cancer cells and resist tumor defenses)
What this could lead to
If successful, this could point toward a new treatment option for advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects from the cell therapy, and the approach may not work for most patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact